AHA again urged the Food and Drug Administration today to allow health system pharmacies to distribute compounded products to other system facilities located more than one mile away. “The AHA is concerned that the one-mile radius limitation [included in draft guidance last year] is not workable for many hospitals and health systems that have centralized their sterile compounding activities in a single location and distribute compounded products to their other system facilities located more than one mile away,” wrote Ashley Thompson, AHA senior vice president for public policy analysis and development, responding to the agency’s request for information on regulatory flexibilities and efficiencies. Instead of the one-mile limit, AHA recommends that the agency allow hospitals and health systems to use the beyond-use date timeframes contained in United States Pharmacopoeia Chapters 797 and 800. AHA also recommended greater FDA oversight of medical device cybersecurity. “We recommend that the FDA proactively set clear measurable expectations for manufacturers before incidents and play a more active role during cybersecurity attacks.”

Related News Articles

Headline
The FBI's Internet Crime Complaint Center released an alert May 7 warning of cyber actors exploiting vulnerabilities in end-of-life routers. Routers dated 2010…
Headline
The FBI’s Internet Criminal Complaint Center May 15 released an alert warning of a malicious text and voice messaging campaign involving impersonators…
Headline
In his latest AHA Cyber Intel blog, John Riggi, AHA national advisor for cybersecurity and risk, examines the state of cyber and physical threats in 2025 as…
Headline
Health care had more cyberthreats last year than any other critical infrastructure industry, according to the FBI's 2024 Internet Crime Report released April…
Headline
The AHA May 12 responded to the Office of Management and Budget's April 11 request for information on regulatory relief, making 100 suggestions to the Trump…
Headline
The Trump administration May 5 issued two executive orders on pharmaceutical manufacturing and life-sciences research. The first executive order, "…